Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725880 | SCV000340221 | pathogenic | not provided | 2016-03-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000169335 | SCV000932569 | pathogenic | Autosomal recessive polycystic kidney disease | 2024-01-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Met238Serfs*7) in the PKHD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PKHD1 are known to be pathogenic (PMID: 19940839). This variant is present in population databases (rs786204588, gnomAD 0.002%). This premature translational stop signal has been observed in individuals with autosomal recessive polycystic kidney disease (PMID: 11898128, 15805161, 19940839). ClinVar contains an entry for this variant (Variation ID: 188960). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000169335 | SCV001163077 | pathogenic | Autosomal recessive polycystic kidney disease | criteria provided, single submitter | clinical testing | ||
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000169335 | SCV001364042 | pathogenic | Autosomal recessive polycystic kidney disease | 2019-12-22 | criteria provided, single submitter | clinical testing | Variant summary: PKHD1 c.711_714delAATG (p.Met238SerfsX7) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 8e-06 in 251376 control chromosomes. c.711_714delAATG has been reported in the literature in individuals affected with Polycystic Kidney and Hepatic Disease (example, Onuchic_2002, Denamur_2010 and Sharp_2005). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Baylor Genetics | RCV003468840 | SCV004204773 | pathogenic | Polycystic kidney disease 4 | 2024-03-25 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000169335 | SCV000220680 | pathogenic | Autosomal recessive polycystic kidney disease | 2018-03-05 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000169335 | SCV002083394 | pathogenic | Autosomal recessive polycystic kidney disease | 2017-11-10 | no assertion criteria provided | clinical testing |